Immune responses to replication-defective HSV-1 type vectors within the CNS: Implications for gene therapy

Gene Therapy

Volumn 10, Issue 11 SPEC., 2003, Pages 941-945

  Bowers, W J ^a   Olschowka, J A ^a   Federoff, H J ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; VIRUS VECTOR; COMPLEMENT INHIBITOR; RECOMBINANT PROTEIN; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

AMPLICON; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CENTRAL NERVOUS SYSTEM; COMPLEMENT INHIBITION; CYTOTOXIC T LYMPHOCYTE; DNA VIRUS; ENDOPLASMIC RETICULUM; GENE EXPRESSION PROFILING; GENE TRANSFER; HERPES SIMPLEX VIRUS 1; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOBIOLOGY; IN VIVO STUDY; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; REVIEW; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS LATENCY; VIRUS RECOMBINANT; VIRUS REPLICATION; ANIMAL; GENE THERAPY; GENE VECTOR; GENETIC ENGINEERING; IMMUNOLOGY; METHODOLOGY; PHYSIOLOGY; VIROLOGY; VIRUS INFECTION;

DNA VIRUSES; HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

ANIMALS; ANTIBODIES, VIRAL; CENTRAL NERVOUS SYSTEM; COMPLEMENT INACTIVATOR PROTEINS; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; HUMANS; RECOMBINANT PROTEINS; VIRAL ENVELOPE PROTEINS; VIRUS DISEASES; VIRUS REPLICATION;

EID: 0037790709     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302047     Document Type: Review

References (58)

1. Kwon BS et al. A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. J Biol Chem 1997; 272: 14272-14276.
2. Montgomery RI, Warner MS, Lum BJ, Spear P. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNG/NGF receptor family. Cell 1996; 87: 427-436.
3. Warner MS et al. A cell surface protein with herpesvirus entry activity (HveB) confers susceptibility to infection by mutants of herpes simplex virus type 1, herpes simplex virus type 2, and pseudorabies virus. Virology 1998; 246: 179-189.
4. Geraghty RJ et al. Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor. Science 1998; 280: 1618-1620.
5. Palella TD et al. Transfer of human HPRT gene sequences into neuronal cells by a herpes simplex virus derived vector. Adv Exp Med Biol 1989; 253A: 549-554.
6. Palella TD et al. Expression of human HPRT mRNA in brains of mice infected with a recombinant herpes simplex virus-1 vector. Gene 1989; 80: 137-144.
7. Corey L, Spear PG. Infections with herpes simplex viruses. N Engl J Med 1986; 314: 686-691.
8. Cantin EM et al. Expression of herpes simplex virus 1 glycoprotein B by a recombinant vaccinia and protection of mice against lethal herpes simplex virus 1 infection. Proc Natl Acad Sci 1999; 84: 5908-5912.
9. Bishop GA, Marlin SD, Schwartz SA, Glorioso JC. Human natural killer cell recognition of herpes simplex virus type 1 glycoproteins: specificity analysis with the use of monoclonal antibodies and antigenic variants. J Immunol 1984; 133: 2206-2214.
10. Davis-Poynter NJ, Farrell HE. Masters of deception: a review of herpesvirus immune evasion strategies. Immunol Cell Biol 1996; 74: 513-522.
11. Banks TA, Rouse BT. Herpesviruses-immune escape artists? Clin Infect Dis 1992; 14: 933-941.
12. Morrison LA. Vaccines against genital herpes: progress and limitations. Drugs 2002; 62: 1119-1129.
13. Dowler KW, Veltri RW. In vitro neutralization of HSV-2: inhibition by binding of normal IgG and purified Fc to virion Fc receptor (FcR). J Med Virol 1984; 13: 251-259.
14. Favoreel HW, Nauwynck HJ, Pensaert MB. Immunological hiding of herpesvirus-infected cells. Arch Virol 2000; 145: 1269-1290.
15. Nagashunmugam T et al. In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc receptor. J Virol 1998; 72: 5351-5359.
16. Frank I, Friedman HM. A novel function of the herpes simplex virus type 1 Fc receptor: participation in bipolar bridging of antiviral immunoglobulin G. J Virol 1989; 63: 4479-4488.
17. Lubinski JM et al. Herpes simplex virus type 1 glycoprotein gC mediates immune evasion in vivo. J Virol 1998; 72: 8257-8263.
18. Hill AB, Barnett BC, McMichael AJ, McGeoch DJ. HLA class I molecules are not transported to the cell surface in cells infected with herpes simplex virus types 1 and 2. J Immunol 1994; 152: 2736-2741.
19. York IA et al. A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell 1994; 77: 525-535.
20. Tigges MA et al. Human CD8+ herpes simplex virus-specific cytotoxic T-lymphocyte clones recognize diverse virion protein antigens. J Virol 1992; 66: 1622-1634.
21. Tomazin R et al. Stable binding of the herpes simplex virus ICP47 protein to the peptide binding site of TAP. EMBO J 1996; 15: 3256-3266.
22. Cunningham AL, Noble JR. Role of keratinocytes in human recurrent herpetic lesions. Ability to present herpes simplex virus antigen and act as targets for T lymphocyte cytotoxicity in vitro. J Clin Invest 1989; 83: 490-496.
23. Spivack JG, Fraser NW. Expression of herpes simplex virus type 1 latency-associated transcripts in the trigeminal ganglia of mice during acute infection and reactivation of latent infection. J Virol 1988; 62: 1479-1485.
24. Ben-Hur T et al. Characterization of RNA transcripts from herpes simplex virus-1 DNA fragment BamHI-B. Virology 1989; 169: 1-8.
25. Thomas SK, Gough G, Latchman DS, Coffin RS. Herpes simplex virus latency-associated transcript encodes a protein which greatly enhances virus growth, can compensate for deficiencies in immediate-early gene expression, and is likely to function during reactivation from virus latency. J Virol 1999; 73: 6618-6625.
26. Dobson AT et al. A latent, nonpathogenic HSV-1-derived vector stably expresses beta-galactosidase in mouse neurons. Neuron 1990; 5: 353-360.
27. Andersen JK, Garber DA, Meaney CA, Breakefield XO. Gene transfer into mammalian central nervous system using herpes virus vectors: extended expression of bacterial lacZ in neurons using the neuron-specific enolase promoter. Hum Gene Ther 1992; 3: 487-499.
28. Bender MA et al. Herpes simplex virus vector-mediated gene transfer to CNS neurons. Soc Neurosci Abstr 1993; 19: 1318.
29. Breakefield XO et al. Gene transfer into the nervous system using recombinant herpes virus vectors. In: Gage (ed). Gene Transfer and Therapy in the Nervous System. Springer-Verlag: Heidelberg, 1992, pp 45-48.
30. Fink DJ et al. In vivo expression of β-galactosidase in hippocampal neurons by HSV mediated gene transfer. Hum Gene Ther 1992; 4: 11-19.
31. Glorioso JC et al. Gene transfer to brain using herpes simplex virus vectors. Ann Neurol 1994 (Suppl 35): S28-S34.
32. Wolfe JH, Deshmane SL, Fraser NW. Herpesvirus vector gene transfer and expression of β-glucuronidase in the central nervous system of MPS VII mice. Nat Genet 1992; 1: 379-384.
33. Marconi P et al. Replication-defective herpes simplex virus vectors for neurotrophic factor gene transfer in vitro and in vivo. Gene Therapy 1999; 6: 904-912.
34. Marconi P et al. Replication-defective herpes simplex virus vectors for gene transfer in vivo. Proc Natl Acad Sci USA 1996; 93: 11319-11320.
35. Johnson PA et al. Cytotoxicity of a replication-defective mutant of herpes simplex virus type I. J Virol 1992; 66: 2952-2965.
36. Krisky DM et al. Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Therapy 1998; 5: 1593-1603.
37. Sena-Esteves M, Saeki Y, Fraefel C, Breakefield XO. HSV-1 amplicon vectors - simplicity and versatility. Mol Ther 2000; 2: 9-15.
38. Fink DJ et al. Design and application of HSV vectors for neuroprotection. Gene Therapy 2000; 7: 115-119.
39. Federoff HJ, Geschwind MD, Geller AI, Kessler JA. Expression of nerve growth factor in vivo, from a defective HSV-1 vector prevents effects of axotomy on sympathetic ganglia. Proc Natl Acad Sci USA 1992; 89: 1636-1640.
40. Frenkel N. Defective interfering herpesviruses. In: Nahmias A, Dowdle W, Scchinazy R (eds). The Human Herpesviruses - An Interdisciplinary Prospective. Elsevier-North Holland, Inc.: New York, 1981, pp 91-120.
41. Frenkel N et al. The herpes simplex virus amplicon - a novel animal-virus cloning vector. In: Gluzman Y (ed). Eucaryotic Viral Vectors. Cold Spring Harbor Laboratory: New York, 1982, pp 205-209.
42. Geller AI, Breakefield XO. A defective HSV-1 vector expresses Escherichia coli β-galactosidase in cultured peripheral neurons. Science 1988; 241: 1667-1669.
43. Geschwind MD, Kessler JA, Geller AI, Federoff HJ. Transfer of the nerve growth factor gene into cell lines and cultured neurons using a defective herpes simplex virus vector. Transfer of the NGF gene into cells by a HSV-1 vector. Mol Brain Res 1994; 24: 327-335.
44. Spaete RR, Frenkel N. The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector. Cell 1982; 30: 305-310.
45. Stow ND, McMonagle E. Propagation of foreign DNA sequences linked to a herpes simplex virus origin of replication. In: Gluzman Y (ed). Eucaryotic Viral Vectors. Cold Spring Harbor Laboratory: New York, 1982, pp 199-204.
46. Wade-Martins R et al. An infectious transfer and expression system for genomic DNA loci in human and mouse cells. Nat Biotechnol 2001; 19: 1067-1070.
47. Saeki Y et al. Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum Gene Ther 1998; 9: 2787-2794.
48. Saeki Y et al. Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol Ther 2001; 3: 591-601.
49. Fraefel C et al. Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J Virol 1996; 70: 7190-7197.
50. Stavropoulos TA, Strathdee CA. An enhanced packaging system for helper-dependent herpes simplex virus vectors. J Virol 1998; 72: 7137-7143.
51. Bowers WJ et al. Expression of vhs and VP16 during HSV-1 helper virus-free amplicon packaging enhances titers. Gene Therapy 2001; 8: 111-120.
52. Bowers WJ, Howard DF, Federoff HJ. Discordance between expression and genome transfer titering of HSV amplicon vectors: recommendation for standardized enumeration. Mol Ther 2000; 1: 294-299.
53. Tolba KA et al. HSV amplicon-mediated delivery of LIGHT enhances the antigen-presenting capacity of chronic lymphocytic leukemia. Mol Ther 2002; 6: 455-463.
54. Hocknell PK et al. Expression of human immunodeficiency virus type 1 gp 120 from herpes simplex virus type 1-derived amplicons results in potent, specific, and durable cellular and humoral immune responses. J Virol 2002; 76: 5565-5580.
55. Tolba KA et al. Development of herpes simplex virus-1 amplicon-based immunotherapy for chronic lymphocytic leukemia. Blood 2001; 98: 287-295.
56. Willis RA et al. Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice. Hum Gene Ther 2001; 12: 1867-1879.
57. Wood MJ et al. Inflammatory effects of gene transfer into the CNS with defective HSV-1 vectors. Gene Therapy 1994; 1: 283-291.
58. Olschowka JA et al. Helper-free HSV-1 amplicons elicit a markedly less robust innate immune response in the CNS. Mol Ther 2003; 7: 218-227.